Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P130029/S013

FLUENCY PLUS ENDOVASCULAR STENT GRAFT

Bard Peripheral Vascular, Inc. · Decision date Aug 13, 2025

FDA DECISIONP130029/S013

What did the FDA decide?

FDA records P130029/S013 as a supplement to PMA P130029, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 13, 2025.

FDA approval order statement

qualification of an additional manufacturing facility for the stent covering process for the Fluency Plus Endovascular Stent Graft
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Aug 13, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P130029/S013
Regulatory pathway
PMA supplement
Product code
PFV
Decision code
OK30
Decision date
Aug 13, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: System, endovascular graft, arteriovenous (AV) dialysis access circuit stenosis treatment.

Product code
PFV
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P130029/S013 received

    Application receipt date recorded by FDA.

  2. P130029/S013 · FDA decision

    30-Day Notice

  3. P130029/S014 · Related supplement

    Bard Fluency Plus Endovascular Stent Graft

  4. P130029/S015 · Related supplement

    Fluency Plus Endovascular Stent Graft

Timeline entries are records held by MedtechLedger for P130029. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P130029

Product / regulatory recordCompanyPathwayDecision dateSource
Bard Peripheral Vascular, Inc.PMA supplementJun 10, 2026FDA
Bard Peripheral Vascular, Inc.PMA supplementJun 22, 2026FDA

Explore the linked device profile

Other records with product code PFV

Product / regulatory recordCompanyPathwayDecision dateSource
Merit Medical Systems, Inc.PMA supplementJun 11, 2026FDA
C.R. Bard, Inc.PMA supplementJun 10, 2026FDA
W. L. Gore & Associates, Inc.PMA supplementMay 26, 2026FDA
C.R. Bard, Inc.PMA supplementDec 16, 2025FDA
Merit Medical Systems, Inc.PMA supplementDec 11, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bard Peripheral Vascular, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1415 W. 3rd St., Tempe, AZ, 85281

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records